仙琚制药，被罚没1.95亿元

Core Viewpoint - Xianju Pharmaceutical has been fined a total of 195 million yuan due to a monopoly agreement with competitors, which significantly impacts its net profit for 2024, accounting for nearly 50% of the projected net profit [2][5][6]. Financial Impact - The total penalty of 195 million yuan includes the confiscation of illegal gains of 23.7467 million yuan and a fine of 171.6 million yuan, which is 8% of the company's 2023 sales [2][5]. - This penalty represents 4.88% of the company's audited revenue for 2024, which is 4.007 billion yuan, and 49.17% of the net profit attributable to shareholders, which is 397 million yuan [5][6]. Company Performance - For the year 2024, Xianju Pharmaceutical reported a revenue of 4.007 billion yuan, a decrease of 2.98% year-on-year, and a net profit of 397 million yuan, down 29.46% year-on-year [8]. - The net profit excluding non-recurring gains and losses was 549 million yuan, reflecting a year-on-year increase of 2.15% [8]. - The net cash flow from operating activities was 399 million yuan, a decrease of 33.05% year-on-year [8]. Compliance and Remediation - Xianju Pharmaceutical has implemented several corrective measures, including stopping the illegal pricing behavior, adjusting the prices of dexamethasone phosphate sodium raw materials, and enhancing internal compliance management [9]. - The company has established an antitrust compliance management guideline and conducted comprehensive risk assessments and specialized training to strengthen compliance [2][9]. Market Position - As of April 30, the stock price of Xianju Pharmaceutical was 8.98 yuan, with a total market capitalization of 8.883 billion yuan [9].